Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are ...
CEO David Zaccardelli sold 4,800 shares of Verona Pharma stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $4.38, for a total transaction of ...
Truist Financial analyst Joon Lee maintained a Buy rating on Verona Pharma (VRNA – Research Report) today. The company’s shares closed yesterday at $38.15. According to TipRanks, Lee is a 5-star ...
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
Get Our Latest Analysis on VRNA Verona Pharma Trading Down 1.7 % Shares of Verona Pharma stock opened at $33.86 on Monday. The company has a current ratio of 8.61, a quick ratio of 8.61 and a ...
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...
Zacks.com on MSN11d
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's WhyVerona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
At the close in NYSE,... ByInvesting.com • Mar 26, 2018 Verona Pharma's RPL554 shows treatment effect in mid-stage CF study; shares up 8% A UK-based Phase 2a clinical trial evaluating Verona ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback